Press Release

30th October 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd. BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Pheroze Jeejeebhoy Tower, Bandra-Kurla Complex, Bandra (E), Dalal Street, Mumbai- 400 001 Mumbai - 400 051 Security Code: 524164 Security Symbol: IOLCP Subject: Press Release – Financial Results for the quarter and half year ended 30th September 2026 Dear Sir, Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release dated 30th October 2026 with respect to the financial results of the Company for the quarter and half year ended 30th September 2026. You are requested to take the same on record. Thanking You, Yours faithfully, for IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr. Vice President & Company Secretary Investor Release IOL Chemicals and Pharmaceuticals Limited Reports Q2 & H1 FY27 Results Records Highest-Ever Quarterly Revenue, EBITDA & PAT Ludhiana, 30th October 2026: IOL Chemicals and Pharmaceuticals Ltd., one of the leading Active Pharmaceutical Ingredient (API) manufacturers, announced its Unaudited Financial Results for the quarter and half year ended 30th September 2026. Q2 FY27 Financial Performance Snapshot (Y-o-Y) (Standalone) Revenue from Operations EBITDA PAT ₹795.0 Cr ₹114.9 Cr ₹65.0 Cr 40.1% 79.6% 116.8% Key Standalone Financial Highlights Particulars (₹ Cr) Q2 FY27 Q2 FY26 Y-o-Y H1 FY27 H1 FY26 Y-o-Y Revenue from Operations 795.0 567.5 40.1% 1551.3 1119.2 38.6% EBITDA 114.9 64.0 79.6% 226.6 133.5 69.7% EBITDA Margin (%) 14.4% 11.1% +321 bps 14.5% 11.8% +270 bps PAT 65.0 30.0 116.8% 129.5 64.0 102.5% PAT Margin (%) 8.1% 5.2% +290 bps 8.3% 5.6% +263 bps Segment Highlights (In ₹ Cr) Pharmaceuticals Chemicals (Net of intersegment) 469.5 472.8 609.1 942.2 322.3 286.8 665.7 336.4 453.5 231.2 136.9 68.8 68.1 75.5 35.5 11.0 40.5 5.1 17.3 23.2 H1 H1 Q2 Q1 Q2 H1 H1 Q2 Q1 Q2 FY26 FY27 FY26 FY27 FY27 FY26 FY27 FY26 FY27 FY27 EBIT Revenue Investor Release Commenting on the performance, Mr. Vikas Gupta, Joint Managing Director said, “We are encouraged by our performance in Q2 FY27, supported by healthy demand across key products and improved operational efficiencies. Our diversified business model has enabled us to sustain growth momentum amid continued geopolitical uncertainties and evolving global market conditions. Better product mix and operating efficiencies also contributed to a 321-basis-point year- on-year expansion in EBITDA margin. Our Pharmaceuticals business continued to perform well, backed by healthy demand across the portfolio. A key highlight was the growing contribution of our non-Ibuprofen portfolio, which registered approximately 70% year-on-year revenue growth and accounted for 45% of pharmaceutical revenue during the quarter, compared with 38% in Q2 FY26. This underscores the progress of our diversification strategy and our efforts to build a broader pharmaceutical portfolio. The Chemicals business also recorded a significant improvement, supported by healthy demand across products. The segment's EBIT contribution increased to approximately 7% from 1% in the corresponding quarter last year, reflecting improved realisations and operating performance. Looking ahead, we are focused on leveraging our established manufacturing capabilities to move further up the value chain. Our forward integration into CDMO and formulation manufacturing is a natural extension of our process expertise, enabling us to provide a wider range of solutions to existing customers, deepen business relationships and unlock new growth opportunities. Going forward, our priorities will remain centred on portfolio diversification, operational excellence and expanding our presence in higher-value manufacturing, while continuing to strengthen our leadership in established product categories. We believe these initiatives will reinforce our competitive positioning and support sustainable long-term growth.” Investor Release About IOL Chemicals and Pharmaceuticals Ltd. IOL Chemicals and Pharmaceuticals Ltd. (IOLCP), established in 1986 and headquartered in Ludhiana, Punjab, is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. It is the world’s largest producer of Ibuprofen with a 30% global market share, among the largest global producers of Iso Butyl Benzene (IBB), and a key manufacturer of Ethyl Acetate in India. IOLCP’s API portfolio spans key therapeutic areas such as pain management, anti-convulsants, anti-diabetics, and cardiovascular care. With exports to over 80 countries—including the USA, UK, China, and Germany—and strong regulatory approvals, the company is well-positioned for global growth. Its backward-integrated operations and ongoing capacity expansion support long-term scalability and resilience. Contact Details IOL Chemicals & Pharmaceuticals Ltd. Investor Relations: MUFG Intime India Pvt. Ltd. Ms. Prachi Ambre CIN: L24116PB1986PLC007030 prachi.ambre@in.mpms.mufg.com Mr. Irfan Raeen Mr. Abhay Raj Singh irfan.raeen@in.mpms.mufg.com Sr. VP & Company Secretary Meeting Request Link Link investor@iolcp.com Website: https://in.mpms.mufg.com/ Safe Harbor Statement Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company’s operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.